Key facts
- Phylos’s last known valuation is $16.0M (Jan 2019).
- It has raised $45.7M; the latest was Later Stage VC ($4.5M) in Dec 2025.
- Notable investors include Slow Ventures, Accomplice VC, V. Gastevich Investments, Arcadian Capital, Artemis Growth Partners — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Phylos
- ·The full record, as it builds
Funding rounds
No funding rounds for Phylos are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Phylos
Operator of an agricultural genomics company intended to enhance the next generation of hemp and cannabis. The company offers a suite of tools using modern molecular genetics and computational biology to provide breeding and research services, enabling cannabis growers and cultivators to understand the breadth of genetics in their catalog, evaluate the development of additional varieties, and drive business growth.
- Sector
- Materials and Resources
- HQ
- Portland, OR, United States
- Employees
- 48
- Website
- phylos.bio/
- Ownership
- Privately Held (backing)
Phylos doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Phylos shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Phylos in its N-PORT filings yet. We sweep new filings monthly.